Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan

We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren–Lawrence grade 2–3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2018/02/01, Vol.41(2), pp.163-171
Main Authors: Morita, Mitsuhiro, Yamada, Kotaro, Date, Hideki, Hayakawa, Kazue, Sakurai, Hidetomo, Yamada, Harumoto
Format: Article
Language:English
Subjects:
Arthritis
Cartilage diseases
Cartilage oligomeric matrix protein
Chondroitin sulfate
clinical trial
Clinical trials
Double-blind studies
Hyaluronic acid
Knee
Matrix protein
Osteoarthritis
Pain
pain-management
Randomization
randomized controlled trial
Sulfates
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03
cites cdi_FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03
container_end_page 171
container_issue 2
container_start_page 163
container_title Biological & pharmaceutical bulletin
container_volume 41
creator Morita, Mitsuhiro
Yamada, Kotaro
Date, Hideki
Hayakawa, Kazue
Sakurai, Hidetomo
Yamada, Harumoto
description We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren–Lawrence grade 2–3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne’s index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne’s index ≥8 or
doi_str_mv 10.1248/bpb.b17-00556
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1969938604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1969938604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03</originalsourceid><addsrcrecordid>eNpdkUtv1DAUhSMEokNhyRZZYsOiKX4lsdmVoZRH0SAKC1aW7VwzHmXswU4Ww0_gV-N0yiAhWdey76dzru6pqqcEnxPKxUuzM-eGdDXGTdPeqxaE8a5uKGnuVwssiahb0oiT6lHOG4xxhyl7WJ1QSbqWtnxR_b50zltt9yg6tFzH0KfoRx_QzTQ4PQJyMaHP2gc3DehjAECrPELUaVynwuVX6AKtAtTfQacz9EWHPm79L-jP0Js4mQHq14MP5fVpGkZvIYyQ0LJ8Fc8B3YxTv0fF7IPe6fC4euD0kOHJ3X1afXt7-XX5rr5eXb1fXlzXtkw_1rwRzLjONQQT0knqpOmJtAI30GJmOmekFJSDZdwBaakVmtOWGMaFlNBjdlq9OOjuUvw5QR7V1mcLw6ADxCkrIlspmWgxL-jz_9BNnFIo0ylKeTkcs5mqD5RNMecETu2S3-q0VwSrOSRVQlIlJHUbUuGf3alOZgv9kf6bSgGuDkDpzouKoWwM_nnb3Bkfh6goJqKIcoJpuZjCpJ1LRximopGz1fKgtMmj_gFHq5KftwPcDsaJonM5Dnjs2rVOCgL7A2I-unQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242244034</pqid></control><display><type>article</type><title>Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan</title><source>Free Full-Text Journals in Chemistry</source><creator>Morita, Mitsuhiro ; Yamada, Kotaro ; Date, Hideki ; Hayakawa, Kazue ; Sakurai, Hidetomo ; Yamada, Harumoto</creator><creatorcontrib>Morita, Mitsuhiro ; Yamada, Kotaro ; Date, Hideki ; Hayakawa, Kazue ; Sakurai, Hidetomo ; Yamada, Harumoto ; Fujita Health University ; aDepartment of Orthopaedic Surgery ; Zeria Pharmaceutical Co ; bConsumer Healthcare Products Development ; Ltd</creatorcontrib><description>We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren–Lawrence grade 2–3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne’s index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne’s index ≥8 or &lt;8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne’s index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months’ therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b17-00556</identifier><identifier>PMID: 29176264</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Arthritis ; Cartilage diseases ; Cartilage oligomeric matrix protein ; Chondroitin sulfate ; clinical trial ; Clinical trials ; Double-blind studies ; Hyaluronic acid ; Knee ; Matrix protein ; Osteoarthritis ; Pain ; pain-management ; Randomization ; randomized controlled trial ; Sulfates</subject><ispartof>Biological and Pharmaceutical Bulletin, 2018/02/01, Vol.41(2), pp.163-171</ispartof><rights>2018 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03</citedby><cites>FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29176264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morita, Mitsuhiro</creatorcontrib><creatorcontrib>Yamada, Kotaro</creatorcontrib><creatorcontrib>Date, Hideki</creatorcontrib><creatorcontrib>Hayakawa, Kazue</creatorcontrib><creatorcontrib>Sakurai, Hidetomo</creatorcontrib><creatorcontrib>Yamada, Harumoto</creatorcontrib><creatorcontrib>Fujita Health University</creatorcontrib><creatorcontrib>aDepartment of Orthopaedic Surgery</creatorcontrib><creatorcontrib>Zeria Pharmaceutical Co</creatorcontrib><creatorcontrib>bConsumer Healthcare Products Development</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><title>Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren–Lawrence grade 2–3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne’s index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne’s index ≥8 or &lt;8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne’s index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months’ therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.</description><subject>Arthritis</subject><subject>Cartilage diseases</subject><subject>Cartilage oligomeric matrix protein</subject><subject>Chondroitin sulfate</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>Double-blind studies</subject><subject>Hyaluronic acid</subject><subject>Knee</subject><subject>Matrix protein</subject><subject>Osteoarthritis</subject><subject>Pain</subject><subject>pain-management</subject><subject>Randomization</subject><subject>randomized controlled trial</subject><subject>Sulfates</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkUtv1DAUhSMEokNhyRZZYsOiKX4lsdmVoZRH0SAKC1aW7VwzHmXswU4Ww0_gV-N0yiAhWdey76dzru6pqqcEnxPKxUuzM-eGdDXGTdPeqxaE8a5uKGnuVwssiahb0oiT6lHOG4xxhyl7WJ1QSbqWtnxR_b50zltt9yg6tFzH0KfoRx_QzTQ4PQJyMaHP2gc3DehjAECrPELUaVynwuVX6AKtAtTfQacz9EWHPm79L-jP0Js4mQHq14MP5fVpGkZvIYyQ0LJ8Fc8B3YxTv0fF7IPe6fC4euD0kOHJ3X1afXt7-XX5rr5eXb1fXlzXtkw_1rwRzLjONQQT0knqpOmJtAI30GJmOmekFJSDZdwBaakVmtOWGMaFlNBjdlq9OOjuUvw5QR7V1mcLw6ADxCkrIlspmWgxL-jz_9BNnFIo0ylKeTkcs5mqD5RNMecETu2S3-q0VwSrOSRVQlIlJHUbUuGf3alOZgv9kf6bSgGuDkDpzouKoWwM_nnb3Bkfh6goJqKIcoJpuZjCpJ1LRximopGz1fKgtMmj_gFHq5KftwPcDsaJonM5Dnjs2rVOCgL7A2I-unQ</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Morita, Mitsuhiro</creator><creator>Yamada, Kotaro</creator><creator>Date, Hideki</creator><creator>Hayakawa, Kazue</creator><creator>Sakurai, Hidetomo</creator><creator>Yamada, Harumoto</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan</title><author>Morita, Mitsuhiro ; Yamada, Kotaro ; Date, Hideki ; Hayakawa, Kazue ; Sakurai, Hidetomo ; Yamada, Harumoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Arthritis</topic><topic>Cartilage diseases</topic><topic>Cartilage oligomeric matrix protein</topic><topic>Chondroitin sulfate</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>Double-blind studies</topic><topic>Hyaluronic acid</topic><topic>Knee</topic><topic>Matrix protein</topic><topic>Osteoarthritis</topic><topic>Pain</topic><topic>pain-management</topic><topic>Randomization</topic><topic>randomized controlled trial</topic><topic>Sulfates</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morita, Mitsuhiro</creatorcontrib><creatorcontrib>Yamada, Kotaro</creatorcontrib><creatorcontrib>Date, Hideki</creatorcontrib><creatorcontrib>Hayakawa, Kazue</creatorcontrib><creatorcontrib>Sakurai, Hidetomo</creatorcontrib><creatorcontrib>Yamada, Harumoto</creatorcontrib><creatorcontrib>Fujita Health University</creatorcontrib><creatorcontrib>aDepartment of Orthopaedic Surgery</creatorcontrib><creatorcontrib>Zeria Pharmaceutical Co</creatorcontrib><creatorcontrib>bConsumer Healthcare Products Development</creatorcontrib><creatorcontrib>Ltd</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morita, Mitsuhiro</au><au>Yamada, Kotaro</au><au>Date, Hideki</au><au>Hayakawa, Kazue</au><au>Sakurai, Hidetomo</au><au>Yamada, Harumoto</au><aucorp>Fujita Health University</aucorp><aucorp>aDepartment of Orthopaedic Surgery</aucorp><aucorp>Zeria Pharmaceutical Co</aucorp><aucorp>bConsumer Healthcare Products Development</aucorp><aucorp>Ltd</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>41</volume><issue>2</issue><spage>163</spage><epage>171</epage><pages>163-171</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>We explored the effects of chondroitin sulfate on knee osteoarthritis in a one-year, randomized, double-blind, dose-comparison study. Patients with painful, Kellgren–Lawrence grade 2–3, osteoarthritis of the knee were treated with oral chondroitin sulfate at a dose of either 260 mg/d (low-dose group, control group) or 1560 mg/d (high-dose group). Symptoms were evaluated by the Lequesne’s index and visual analog scale for pain. We made subgroup analyses according to background symptom severity (Lequesne’s index ≥8 or &lt;8) in 73 patients. Serum level of cartilage oligomeric matrix protein and hyaluronic acid were also determined. In the subgroup with severe symptoms (Lequesne’s index ≥8), the chondroitin sulfate dose of 1560 mg/d improved pain faster after 6 and 9 months’ therapy. However, no dose-related effects were found on cartilage oligomeric matrix protein or hyaluronic acid levels. Chondroitin sulfate also had good tolerability. We conclude that chondroitin sulfate is useful for pain control in knee osteoarthritis.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>29176264</pmid><doi>10.1248/bpb.b17-00556</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2018/02/01, Vol.41(2), pp.163-171
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_1969938604
source Free Full-Text Journals in Chemistry
subjects Arthritis
Cartilage diseases
Cartilage oligomeric matrix protein
Chondroitin sulfate
clinical trial
Clinical trials
Double-blind studies
Hyaluronic acid
Knee
Matrix protein
Osteoarthritis
Pain
pain-management
Randomization
randomized controlled trial
Sulfates
title Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T04%3A07%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Chondroitin%20Sulfate%20for%20Painful%20Knee%20Osteoarthritis:%20A%20One-Year,%20Randomized,%20Double-Blind,%20Multicenter%20Clinical%20Study%20in%20Japan&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Morita,%20Mitsuhiro&rft.aucorp=Fujita%20Health%20University&rft.date=2018-02-01&rft.volume=41&rft.issue=2&rft.spage=163&rft.epage=171&rft.pages=163-171&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b17-00556&rft_dat=%3Cproquest_cross%3E1969938604%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c702t-4583bf7f51011792f9bd19c805e603b7fb99824ec34fe162c8a4261b34899ed03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2242244034&rft_id=info:pmid/29176264&rfr_iscdi=true